Trump Spoils Pharma Chiefs With No More Bad News on Drug Pricing

President promises to lower taxes, speed regulatory approvals
But Medicare price bidding is still up for negotiation

Heads of pharmaceutical companies at the White House after meeting with Donald Trump on Jan. 31.
Photographer: Andrew Harrer/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Anna Edney and Jared S Hopkins

February 1, 2017 at 12:00 AM UTC

This article is for subscribers only.

For drugmakers, Tuesday’s meeting with President Donald Trump was a dose of happy pills.

Though there’s still worrisome ambiguity on the subject, Trump appeared to back off the worst-case scenario for pharma companies -- the U.S. government won’t be setting drug prices.